New obesity drug tested in kidney patients: dosing clues sought

NCT ID NCT07141030

Recruiting now Knowledge-focused Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a single dose of the drug GZR18 in 32 adults who are overweight or obese, some with mild to severe kidney problems and some with normal kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to find the right dose for people with kidney issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR18 injection
What this could lead to: If successful, this study could help doctors determine the right dose of GZR18 for people with kidney problems, making treatment safer and more effective.
What could go wrong: This is a very early phase 1 study with only 32 participants, so results may not apply to everyone. The drug may still have side effects or fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Gan & Lee Pharmaceuticals
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.